Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Human VGFR3 Antibodies:
anti-Mouse (Murine) VGFR3 Antibodies:
Go to our pre-filtered search.
Human Monoclonal VGFR3 Primary Antibody for IHC (p), WB - ABIN387818
Romero, Friel, Velez Edwards, Kusanovic, Hassan, Mazaki-Tovi, Vaisbuch, Kim, Erez, Chaiworapongsa, Pearce, Bartlett, Salisbury, Anant, Vovis, Lee, Gomez, Behnke, Oyarzun, Tromp, Williams, Menon: A genetic association study of maternal and fetal candidate genes that predispose to preterm prelabor rupture of membranes (PROM). in American journal of obstetrics and gynecology 2010
Show all 6 Pubmed References
Rare inherited and de novo variants in 2,871 congenital heart disease probands identified GDF1 (show GDF1 Antibodies), MYH6 (show MYH6 Antibodies), and FLT4 (show FLT4 Antibodies) as causative genes.
Data show that VEGF-C (show VEGFC Antibodies), VEGF-D (show Figf Antibodies), and VEGFR-3 (show FLT4 Antibodies) were expressed in a substantial percentage of breast carcinomas.
There was a significant decrease in VEGFR3 (show FLT4 Antibodies) expression in pulmonary arterial endothelial cells from pulmonary arterial hypertension patients.
By treating LECs with VEGF (show VEGFA Antibodies)-C156S and analyzing subsequent changes in gene expression, we identified several 'immediate early (show JUN Antibodies)' transcription factors that showed a rapid transient upregulation VEGFR-3 (show FLT4 Antibodies) stimulation. these results reveal an important and unanticipated role of HOXD10 (show HOXD10 Antibodies) in the regulation of VEGFR-3 (show FLT4 Antibodies) signaling in lymphatic endothelial cells, and in the control of lymphangiogenesis and permeability.
The normalized methylation values for the VEGFR1 (show FLT1 Antibodies), VEGFR2 (show KDR Antibodies) and VEGFR3 (show FLT4 Antibodies) promoters tended to be higher in the tumour cell lines than in normal tonsil samples, whereas amounts of VEGFR1 (show FLT1 Antibodies), VEGFR2 (show KDR Antibodies) and VEGFR3 (show FLT4 Antibodies) messenger RNA were significantly higher
These results indicate that VEGF-C (show VEGFC Antibodies)-induced MSC (show MSC Antibodies) osteogenesis is mediated through VEGFR2 (show KDR Antibodies) and VEGFR3 (show FLT4 Antibodies), and followed the activation of the ERK (show EPHB2 Antibodies)/RUNX2 (show RUNX2 Antibodies) signaling pathway.
Assessment of VEGFR-2/VEGFR (show KDR Antibodies)-3 (show FLT4 Antibodies) on tumor samples might serve as a putative prognostic factor in renal cell carcinoma (show MOK Antibodies) cases, identifying a subset of patients that may benefit from antiangiogenic treatments targeting VEGFR (show KDR Antibodies) receptors.
This study suggests that NRP1 (show NELL1 Antibodies) expression and LVD are independent factors that are likely to predict the risk of LN metastasis in squamous cell carcinoma (SCC (show CYP11A1 Antibodies))of the tongue, whereas the expression of VEGFC (show VEGFC Antibodies), VEGFR3 (show FLT4 Antibodies), CCR7 (show CCR7 Antibodies), and SEMA3E (show SEMA3E Antibodies) are nonindependent predictive factors
Data indicate that vascular endothelial growth factor D (VEGF-D (show Figf Antibodies)) was the best indicator of metastasis and vascular endothelial growth factors and receptor-3 (VEGFR-3 (show FLT4 Antibodies)) may help to determine the prognosis and management of colorectal cancer (CRC (show CALR Antibodies)).
The summarizes the structure and function features of pathway-related molecules of VEGFC (show VEGFC Antibodies)/D-VEGFR3 (show FLT4 Antibodies)/NRP2 (show NELL2 Antibodies) axis, stages of various tumors and their molecular mechanisms and significances in tuthe expression changes of these molecules in different anatomic organs or histopathologic types or development lymphatic metastasis.
This gene encodes a tyrosine kinase receptor for vascular endothelial growth factors C and D. The protein is thought to be involved in lymphangiogenesis and maintenance of the lymphatic endothelium. Mutations in this gene cause hereditary lymphedema type IA.
, fms-like tyrosine kinase 4
, soluble VEGFR3 variant 1
, soluble VEGFR3 variant 2
, soluble VEGFR3 variant 3
, tyrosine-protein kinase receptor FLT4
, vascular endothelial growth factor receptor 3